Evaluating MERS-CoV Entry Pathways
Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic pathogen with a broad host range. The extent of MERS-CoV in nature can be traced to its adaptable cell entry steps. The virus can bind host-cell carbohydrates as well as proteinaceous receptors. Following receptor interaction, the virus can utilize diverse host proteases for cleavage activation of virus-host cell membrane fusion and subsequent genome delivery. The fusion and genome delivery steps can be completed at variable times and places, either at or near cell surfaces or deep within endosomes. Investigators focusing on the CoVs have developed several methodologies that effectively distinguish these different cell entry pathways. Here we describe these methods, highlighting virus-cell entry factors, entry inhibitors, and viral determinants that specify the cell entry routes. While the specific methods described herein were utilized to reveal MERS-CoV entry pathways, they are equally suited for other CoVs, as well as other protease-dependent viral species.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2099 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2099(2020) vom: 27., Seite 9-20 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qing, Enya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.09.2020 Date Revised 21.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-0211-9_2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304830925 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304830925 | ||
| 003 | DE-627 | ||
| 005 | 20231225115830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-0211-9_2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1016.xml |
| 035 | |a (DE-627)NLM304830925 | ||
| 035 | |a (NLM)31883084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qing, Enya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating MERS-CoV Entry Pathways |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.09.2020 | ||
| 500 | |a Date Revised 21.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic pathogen with a broad host range. The extent of MERS-CoV in nature can be traced to its adaptable cell entry steps. The virus can bind host-cell carbohydrates as well as proteinaceous receptors. Following receptor interaction, the virus can utilize diverse host proteases for cleavage activation of virus-host cell membrane fusion and subsequent genome delivery. The fusion and genome delivery steps can be completed at variable times and places, either at or near cell surfaces or deep within endosomes. Investigators focusing on the CoVs have developed several methodologies that effectively distinguish these different cell entry pathways. Here we describe these methods, highlighting virus-cell entry factors, entry inhibitors, and viral determinants that specify the cell entry routes. While the specific methods described herein were utilized to reveal MERS-CoV entry pathways, they are equally suited for other CoVs, as well as other protease-dependent viral species | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Coronavirus (CoV) | |
| 650 | 4 | |a Endosome | |
| 650 | 4 | |a HR2 peptide | |
| 650 | 4 | |a IFITM3 | |
| 650 | 4 | |a Middle East respiratory syndrome (MERS) | |
| 650 | 4 | |a Protease | |
| 650 | 4 | |a Protease inhibitor | |
| 650 | 4 | |a Pseudovirus | |
| 650 | 4 | |a Spike (S) | |
| 650 | 4 | |a TMPRSS2 | |
| 650 | 4 | |a Transfection | |
| 650 | 4 | |a Viral entry | |
| 650 | 4 | |a Virus concentration | |
| 650 | 4 | |a Virus purification | |
| 650 | 7 | |a IFITM3 protein, human |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a RNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Peptide Hydrolases |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a Serine Endopeptidases |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 650 | 7 | |a TMPRSS2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 700 | 1 | |a Hantak, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Galpalli, Gautami G |e verfasserin |4 aut | |
| 700 | 1 | |a Gallagher, Tom |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2099(2020) vom: 27., Seite 9-20 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2099 |g year:2020 |g day:27 |g pages:9-20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-0211-9_2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2099 |j 2020 |b 27 |h 9-20 | ||